Phase 2 Trial of Tomivosertib Begins Dosing Advanced Castration-resistant PC Patients

Phase 2 Trial of Tomivosertib Begins Dosing Advanced Castration-resistant PC Patients
A Phase 2 clinical trial evaluating eFFECTOR Therapeutics' investigational therapy tomivosertib (eFT508), for men with advanced castrate-resistant prostate cancer (CRPC) who failed to respond to androgen receptor signaling (ARS) inhibitors, has begun dosing patients. The trial (NCT03690141), currently recruiting participants, will evaluate the safety, tolerability and antitumor activity of tomivosertib in patients whose disease progressed while on treatment with the ARS inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide). Thirty patients w
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *